Results 181 to 190 of about 1,336,088 (341)

First impressions: A prospective evaluation of patient-physician concordance and satisfaction following the initial medical oncology consultation. [PDF]

open access: yesCancer Med, 2023
Bach Y   +20 more
europepmc   +1 more source

FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study [PDF]

open access: bronze, 1998
Emilio Bajetta   +11 more
openalex   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

open access: yesMolecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra   +10 more
wiley   +1 more source

Supplementum 283: Abstracts of the Swiss Oncology & Hematology Congress (SOHC)

open access: yesSwiss Medical Weekly
Swiss Society of Medical Oncology   +2 more
doaj   +1 more source

Implementing Ryan's Law on an Inpatient Medical Oncology Unit. [PDF]

open access: yesClin J Oncol Nurs
McKaig A   +4 more
europepmc   +1 more source

Medical Oncology [PDF]

open access: yes, 2018
林 龍二   +2 more
core   +2 more sources

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy